Tag : PATIENT-REPORTED OUTCOMES

CONFERENCE UPDATE

Long-term HRQoL outcomes of dostarlimab + chemotherapy in patients with primary advanced or recurrent EC from the RUBY trial
Dostarlimab in conjunction with carboplatin-paclitaxel (CP) has previously been shown to significantly improve progression-free survival (PFS) and overall survival (OS) outcomes compared with CP alone in patients with primary advanced or recurrent endometrial cancer (EC).1 This has led to its approval in the first line for EC patients in the mismatch repair deficient (dMMR) microsatellite instability-high (MSI-H) population. However, more data are required to describe the health-related quality of life (HRQoL) of this immunotherapy CP combination over extended periods.
CONFERENCE UPDATE

HRQoL improvements with pembrolizumab + CCRT and EBRT in high-risk LACC patients in ENGOT-CX11/GOG-3047/KEYNOTE A18